<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>S-allylmercaptocysteine (SAMC), one of the water-soluble organosulfur garlic derivatives, has been demonstrated as a suppressive agent against some <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The effects of SAMC on the proliferation and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) under in vitro and in vivo conditions were evaluated here </plain></SENT>
<SENT sid="2" pm="."><plain>The viabilities and migrations of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells SW480, SW620, Caco-2 treated with SAMC were measured by <z:chebi fb="0" ids="53233">MTT</z:chebi>, scratch-wound, and transwell assays </plain></SENT>
<SENT sid="3" pm="."><plain>The in vivo anticancer effect of SAMC against luciferase-expressing SW620 xenografts in mice was determined by bioluminescence imaging and histopathology observation </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of SAMC-treated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells was examined by Western blotting </plain></SENT>
<SENT sid="5" pm="."><plain>The results demonstrate that SAMC could effectively suppress the growth and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells both in vivo and in vitro </plain></SENT>
<SENT sid="6" pm="."><plain>The anticancer effect of SAMC was related to the decreased proliferation and <z:mp ids='MP_0006042'>increased apoptosis</z:mp> as well as <z:mp ids='MP_0001651'>necrosis</z:mp> of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="7" pm="."><plain>Oral administration of SAMC in the quantity/concentration used had no apparent toxic side effect on the vital organs of the experimental mice </plain></SENT>
<SENT sid="8" pm="."><plain>Taken together, the proliferation and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells can be significantly suppressed by SAMC treatment under both in vitro and in vivo conditions </plain></SENT>
<SENT sid="9" pm="."><plain>SAMC may thus be a promising candidate for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> chemotherapy </plain></SENT>
</text></document>